Síndrome metabólico: relación entre obesidad, resistencia a la insulina e hipertensión sistemica en pequeños animales
Palabras clave:
perros, colesterol, endocrinopatia, gatos, triglicéridosResumen
La presente revisión objetiva definir el síndrome metabólico y la acción del tejido adiposo
sobre la resistencia a la insulina e hipertensión arterial sistémica en pequeños animales
(Perros y gatos). El síndrome metabólico, típico en individuos obesos, es considerado un
conjunto de factores de riesgo, que los predispone al desarrollo de resistencia a la insulina e
hipertensión arterial, que puede llevar a cuadros endocrinos, como diabetes mellitus tipo 2 y
enfermedades cardiovasculares. Este se caracteriza por obesidad, hipertrigliceridemia,
hipercolesteronemia, hipertensión arterial sistémica y un ligero aumento de la glicemia sérica
en ayuno. Se sabe que el tejido adiposo funciona como un importante órgano endocrino,
secretando factores que ayudan al aumento de la glicemia, disminución de la acción de la
insulina y aumento de la presión arterial en el organismo. El tratamiento del síndrome
principalmente es basado en actividad física y la dieta. A pesar de ser diagnosticada
frecuentemente en medicina, todavía hay dudas en medicina veterinaria sobre su existencia y
mecanismos fisiopatológicos, de este modo se deben realizar más estudios en el área.
Citas
Han TS, Lean ME. Metabolic Syndrome. Medicine. 2006; 34:12:536-542.
Abraham NG, Brunner EJ, Eriksson JW, Robertson RP. Metabolic syndrome. Ann N Y Acad Sci. 2007; 1113:256-275.
Opie LH. Metabolic Syndrome. Circulation. 2007; 115:e32-e35.
Radin MJ, Sharkey LC, Holycross BJ. Adipokines: a review of biological and analytical principles and an update in dogs, cats, and horses. Vet Clin Path. 2009; 38:136-156.
Zoran DL. Obesity in Dogs and Cats: A Metabolic and Endocrine Disorder. Vet Clin North Am Small Anim Pract. 2010; 40:221-239.
Hanley AJ, Karter AJ, Williams K, Festa A, D’Agostino Jr RB, Wagenknecht LE, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005; 112:3713-3721.
Luna RL. Síndrome Metabólica. Arq Bras Cardiol. 2007; 88:5:e124-e126.
Hollenbeck C, Reaven GM. Variations in insulin stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987; 64:1169-1173.
Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988; 37:1595-1607.
Güçlü F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother. 2004; 58:614-618.
Jager J, Grémeaux T, Cormont M, Marchand-Brustel Y, Tanti JF. Interleukin-1β-Induced Insulin Resistance in Adipocytes through Down-Regulation of Insulin Receptor Substrate-1 Expression. Endocrinology. 2007; 148:1:241-251.
Giestas A, Palma I, Ramos MH. Sistema Renina Angiotensina e sua modulação farmacológica. Acta Med Port. 2010; 23:4:677-688.
Engeli, S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, et al. The adipose tissue renin-angiotensinaldosterone system: role in the metabolic syndrome. Int J Biochem Cell Biol. 2003; 35:807-825.
Carvalho MHC, Colaço AL, Fortes ZB. Citocinas, Disfunção Endotelial e Resistência à Insulina. Arq Bras Endocrinol Metab. 2006; 50:2:304-312.
Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins, Leukot Essent Fatty Acids. 1999; 60:401-405.
Egan BM, Greene EL, Goodfriend TL. Insulin Resistance and Cardiovascular Disease. Am J Hypertens. 2001; 14:16:116S-125S.
Bülow J, Madsen J, Højgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest. 1990; 50:291-296.
Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity – related insulin resistance. Physiol Behav. 2008; 94:206-218.
Appleton DJ, Rand JS, Sunvold GD. Plasma leptin concentrations are independently associated with insulin sensitivity in lean and overweight cats. J Feline Med Surg. 2002; 4:83-93.
Ishioka K, Hosoya K, Kitagawa H, Shibata H, Honjoh T, Kimura K. Plasma leptin concentration in dogs:effects of body condition score, age, gender, and breeds. Res Vet Sci. 2007; 82:11-15.
Moller DE. Potential role of TNF alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000; 11:212-217.
Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005; 19:547-566.
Gayet C, Bailhache E, Dumon H, Martin L, Siliart B, Nguyen P. Insulin resistance and changes in plasma concentrations of TNFa, IGF1, and NEFA in dogs during weight gain and obesity. J Anim Physiol Anim Nutr. 2004; 88:157-165.
Helisch A. Arteriogenesis: the development and growth of collateral arteries. Microcirculation. 2003; 10:83-97.
Russel JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol. 2006; 15:318-330.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial 4.0 Internacional.
